<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043480</url>
  </required_header>
  <id_info>
    <org_study_id>2020/01181</org_study_id>
    <nct_id>NCT05043480</nct_id>
  </id_info>
  <brief_title>Pilot Study On Pulsed Electromagnetic Field Therapy For Osteosarcopenia</brief_title>
  <official_title>Pilot Study On Pulsed Electromagnetic Field Therapy For Osteosarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louis Tee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National University, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexandra Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single-site, single arm pilot study aims to assess the efficacy of Pulsed&#xD;
      Electromagnetic Field (PEMF) exposure in the reduction of the decline in muscle strength,&#xD;
      function and bone mineral density (BMD) in osteosarcopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, single-site, single-arm pilot study aims to assess the efficacy of Pulsed&#xD;
      Electromagnetic Field (PEMF) exposure in the reduction of the decline in muscle strength,&#xD;
      function and bone mineral density (BMD) in osteo-sarcopenia. For this pilot study, we will&#xD;
      recruit 80 participants aged 65 years old and greater with osteo-sarcopenia, to receive PEMF&#xD;
      therapy, at 1.5mT, once a week for 10 min to alternate lower limb (10 mins each week) weekly&#xD;
      for 16 weeks. Participants will be followed up at baseline, 4, 8 and 12 and 17 weeks. At each&#xD;
      follow-up, falls risk will be assessed by Short Physical Performance Battery (SPPB),&#xD;
      including 6-minute walk and 5 sit-to-stand tests, Falls Efficacy Scale International (FESI),&#xD;
      3min-NS (3 minute Nutritional Screening) and SARC-F (Strength, Assistance with Walking, Rise&#xD;
      from Chair, Climb Stairs and Falls) questionnaires. Muscle strength (hand grip and leg&#xD;
      extension) and calf diameter are measured. Blood tests, saliva tests, and DEXA scans will be&#xD;
      done at baseline, immediately after first PEMF exposure and week 17 to determine changes in&#xD;
      biomarkers for senescence, bone/fat/muscle composition and skeletal muscle mass.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower limb strength</measure>
    <time_frame>18 weeks</time_frame>
    <description>Lower limb strength measurement measured by dynamometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>18 weeks</time_frame>
    <description>Handgrip strength measurement measured by dynamometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Physical Performance Battery (SPPB)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Validated assessment tool for balance and lower limb strength (Score from 0 to 12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minute walk test (6MWT)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Distance walked in a time of 6 minutes (units of meters)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lean muscle and fat mass</measure>
    <time_frame>18 weeks</time_frame>
    <description>Lean muscle and fat mass measured by DEXA scan</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Osteopenia or Osteoporosis</condition>
  <arm_group>
    <arm_group_label>PEMF arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this single-arm study, all participants will be assigned to the intervention arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PEMF</intervention_name>
    <description>Participants will receive pulsed electromagnetic fields (PEMF) exposure to alternate lower limbs weekly for 16 weeks. Participants will place alternate lower limb into the PEMF machine. Each lower limb will be exposed to 1.5mT magnetic field exposure for 10 mins once a week (total 10 min each week) for 16 weeks.</description>
    <arm_group_label>PEMF arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 65 years old and above, which corresponds to the geriatric patient population seen&#xD;
             at the Healthy Ageing clinics and wards&#xD;
&#xD;
          2. Diagnosed with primary osteopenia, including primary osteoporosis, by BMD measurements&#xD;
             on DEXA scans&#xD;
&#xD;
          3. Diagnosed with sarcopenia by SARC-F&#xD;
&#xD;
          4. Willing and able to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of metallic implants, pacemakers or insulin pumps&#xD;
&#xD;
          2. Presence of rheumatological disease (such as osteoarthritis or rheumatoid arthritis)&#xD;
&#xD;
          3. Presence of secondary osteoporosis (such as hyperparathyroidism, steroid-induced&#xD;
             osteoporosis)&#xD;
&#xD;
          4. Presence of end-stage organ failure, including severe dementia or cancer&#xD;
&#xD;
          5. Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santhosh Seetharaman, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Santhosh Seetharaman, MBBS</last_name>
    <phone>90302683</phone>
    <email>mdcsnks@nus.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>159964</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>Santhosh Seetharaman, MBBS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Yap JLY, Tai YK, Fröhlich J, Fong CHH, Yin JN, Foo ZL, Ramanan S, Beyer C, Toh SJ, Casarosa M, Bharathy N, Kala MP, Egli M, Taneja R, Lee CN, Franco-Obregón A. Ambient and supplemental magnetic fields promote myogenesis via a TRPC1-mitochondrial axis: evidence of a magnetic mitohormetic mechanism. FASEB J. 2019 Nov;33(11):12853-12872. doi: 10.1096/fj.201900057R. Epub 2019 Sep 13.</citation>
    <PMID>31518158</PMID>
  </reference>
  <reference>
    <citation>Parate D, Kadir ND, Celik C, Lee EH, Hui JHP, Franco-Obregón A, Yang Z. Pulsed electromagnetic fields potentiate the paracrine function of mesenchymal stem cells for cartilage regeneration. Stem Cell Res Ther. 2020 Feb 3;11(1):46. doi: 10.1186/s13287-020-1566-5.</citation>
    <PMID>32014064</PMID>
  </reference>
  <reference>
    <citation>Kurth F, Tai YK, Parate D, van Oostrum M, Schmid YRF, Toh SJ, Yap JLY, Wollscheid B, Othman A, Dittrich PS, Franco-Obregón A. Cell-Derived Vesicles as TRPC1 Channel Delivery Systems for the Recovery of Cellular Respiratory and Proliferative Capacities. Adv Biosyst. 2020 Nov;4(11):e2000146. doi: 10.1002/adbi.202000146. Epub 2020 Sep 2.</citation>
    <PMID>32875708</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Alexandra Hospital</investigator_affiliation>
    <investigator_full_name>Louis Tee</investigator_full_name>
    <investigator_title>Senior Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

